| 摘要 |
A biomarker that correlates to treatment with drugs that inhibit FMS is disclosed. This biomarker has been shown to have utility in assessing response to the compounds. The plasma level of the biomarker is increased upon treatment with FMS inhibitor compounds, thus indicating that this biomarker is involved in FMS activity. |
